Contrast-Induced NephropathyNCT07855653
Uric Acid to Albumin Ratio for Predicting Contrast Associated Acute Kidney Injury After Cardiac and Non Cardiac Procedures
An observational study of Contrast-Induced Nephropathy and Acute Kidney Injury, run by Assiut University.
Trial summary
Contrast-associated acute kidney injury (CA-AKI) is a potential complication that can occur following exposure to iodinated contrast media during diagnostic and interventional procedures, contributing to prolonged hospital stays, increased morbidity, and higher mortality. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Contrast-Induced Nephropathy, Acute Kidney Injury
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Nov 2026to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Adult patients admitted to or evaluated at the Internal Medicine Department and related catheterization and interventional units at Assiut University Hospital who are scheduled to undergo cardiac (percutaneous coronary intervention) or non-cardiac diagnostic and interventional procedures requiring exposure to iodinated contrast media.
Who may be able to join
- Adult patients aged 18 years or older undergoing a cardiac or non-cardiac procedure requiring iodinated contrast media.
- Cardiac group: patients undergoing percutaneous coronary intervention (PCI).
- Non-cardiac group: patients undergoing other diagnostic or interventional contrast procedures.
- Provision of written informed consent prior to enrollment.
- Available baseline (pre-procedural) serum creatinine, uric acid, and albumin measurements.
Who cannot join
- Severe chronic kidney disease or end-stage renal disease on regular maintenance hemodialysis (baseline eGFR < 15 mL/min/1.73 m^2).
- Exposure to iodinated contrast media within the preceding 7 to 10 days.
- Acute kidney injury from any cause present at admission or prior to contrast exposure.
- Active infection, sepsis, or systemic inflammatory response syndrome at the time of enrollment.
- Known history of gout, current use of urate-lowering therapy, or hematologic malignancy affecting uric acid metabolism.
- Severe hepatic disease or marked proteinuria affecting serum albumin independently of the study condition.
Show all 10Show fewer
- Emergent PCI where baseline laboratory samples could not be obtained prior to contrast exposure.
- Patient death occurring before the 48 to 72 hour post-procedural serum creatinine evaluation could be performed.
- Pregnancy.
- Refusal of informed consent or loss to follow-up prior to outcome assessment.
About this study
Official title: Predictive Value of the Uric Acid to Albumin Ratio for Contrast Associated Acute Kidney Injury After Cardiac and Non Cardiac Procedures
Contrast-associated acute kidney injury (CA-AKI) is a potential complication that can occur following exposure to iodinated contrast media during diagnostic and interventional procedures, contributing to prolonged hospital stays, increased morbidity, and higher mortality. Although several clinical risk factors are well-recognized, pre-procedural risk stratification remains challenging. The serum uric acid-to-albumin ratio (UAR) has emerged as a composite biomarker reflecting oxidative stress and inflammation that may help identify vulnerable patients prior to contrast exposure.
The primary purpose of this prospective observational cohort study is to evaluate the predictive performance of the pre-procedural uric acid-to-albumin ratio for the development of contrast-associated acute kidney injury. The study will also compare the predictive value of UAR between patients undergoing cardiac procedures, specifically percutaneous coronary intervention (PCI), and those undergoing non-cardiac contrast procedures.
A total of 100 adult participants will be enrolled across two groups: 50 patients undergoing PCI and 50 patients undergoing non-cardiac contrast procedures. Baseline venous blood samples will be obtained prior to the procedure to measure serum creatinine, uric acid, and albumin levels. Follow-up kidney function tests will be evaluated at 48 and 72 hours post-procedure to detect the development of CA-AKI and assess the diagnostic accuracy of pre-procedural UAR.
- Conditions
- Contrast-Induced Nephropathy, Acute Kidney Injury
- Keywords
- Uric acid to albumin ratio, UAR, Contrast-associated acute kidney injury, Percutaneous coronary intervention, Iodinated contrast media, Cardiac catheterization, Mehran risk score
- Medical subject headings
- Acute Kidney Injury
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Cardiac Group (PCI) | Adult patients undergoing percutaneous coronary intervention (PCI) requiring exposure to iodinated contrast media. Baseline serum creatinine, uric acid, and albumin are measured pre-procedure, and renal function is monitored at 48 and 72 hours post-procedure to assess the development of contrast-associated acute kidney injury (CA-AKI). | |
| Non-Cardiac Group | Adult patients undergoing non-cardiac diagnostic or interventional procedures requiring exposure to iodinated contrast media. Baseline serum creatinine, uric acid, and albumin are measured pre-procedure, and renal function is monitored at 48 and 72 hours post-procedure to assess the development of contrast-associated acute kidney injury (CA-AKI). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Contrast-Associated Acute Kidney Injury (CA-AKI)
Defined as an absolute increase in serum creatinine of at least 0.5 mg/dL (44.2 micromol/L) or a relative increase of at least 25% from baseline, evaluated within 72 hours following iodinated contrast media exposure.
Measured: 72 hours post-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2026
- Study startNov 2026 (estimated)
- Primary completionNov 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Contrast-Induced NephropathyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maher Nasser Rsof Atia, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07855653
- Sponsor's protocol ID
- UAR in Contrast-Associated AKI
- Status last verified
- Sep 2026
- First submitted
- 28 Sep 2026
- Last updated
- 2 Oct 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictive Value of the Uric Acid to Albumin Ratio for Contrast Associated Acute Kidney Injury After Cardiac and Non Cardiac Procedures
- ClinicalTrials.gov ID
- NCT07855653
- Acronym / sponsor ID
- UAR in Contrast-Associated AKI
- Conditions
- Contrast-Induced Nephropathy, Acute Kidney Injury
- Keywords
- Uric acid to albumin ratio, UAR, Contrast-associated acute kidney injury, Percutaneous coronary intervention, Iodinated contrast media, Cardiac catheterization, Mehran risk score
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Nov 2026 (estimated)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 2 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Contrast-associated acute kidney injury (CA-AKI) is a potential complication that can occur following exposure to iodinated contrast media during diagnostic and interventional procedures, contributing to prolonged hospital stays, increased morbidity, and higher mortality. Although several clinical risk factors are well-recognized, pre-procedural risk stratification remains challenging. The serum uric acid-to-albumin ratio (UAR) has emerged as a composite biomarker reflecting oxidative stress and inflammation that may help identify vulnerable patients prior to contrast exposure.
The primary purpose of this prospective observational cohort study is to evaluate the predictive performance of the pre-procedural uric acid-to-albumin ratio for the development of contrast-associated acute kidney injury. The study will also compare the predictive value of UAR between patients undergoing cardiac procedures, specifically percutaneous coronary intervention (PCI), and those undergoing non-cardiac contrast procedures.
A total of 100 adult participants will be enrolled across two groups: 50 patients undergoing PCI and 50 patients undergoing non-cardiac contrast procedures. Baseline venous blood samples will be obtained prior to the procedure to measure serum creatinine, uric acid, and albumin levels. Follow-up kidney function tests will be evaluated at 48 and 72 hours post-procedure to detect the development of CA-AKI and assess the diagnostic accuracy of pre-procedural UAR.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cardiac Group (PCI) | – | –Adult patients undergoing percutaneous coronary intervention (PCI) requiring exposure to iodinated contrast media. Baseline serum creatinine, uric acid, and albumin are measured pre-procedure, and renal function is monitored at 48 and 72 hours post-procedure to assess the development of contrast-associated acute kidney injury (CA-AKI). |
| Non-Cardiac Group | – | –Adult patients undergoing non-cardiac diagnostic or interventional procedures requiring exposure to iodinated contrast media. Baseline serum creatinine, uric acid, and albumin are measured pre-procedure, and renal function is monitored at 48 and 72 hours post-procedure to assess the development of contrast-associated acute kidney injury (CA-AKI). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adult patients admitted to or evaluated at the Internal Medicine Department and related catheterization and interventional units at Assiut University Hospital who are scheduled to undergo cardiac (percutaneous coronary intervention) or non-cardiac diagnostic and interventional procedures requiring exposure to iodinated contrast media.
Key inclusion criteria (5 listed)
- Adult patients aged 18 years or older undergoing a cardiac or non-cardiac procedure requiring iodinated contrast media.
- Cardiac group: patients undergoing percutaneous coronary intervention (PCI).
- Non-cardiac group: patients undergoing other diagnostic or interventional contrast procedures.
- Provision of written informed consent prior to enrollment.
- Available baseline (pre-procedural) serum creatinine, uric acid, and albumin measurements.
Key exclusion criteria (10 listed)
- Severe chronic kidney disease or end-stage renal disease on regular maintenance hemodialysis (baseline eGFR < 15 mL/min/1.73 m^2).
- Exposure to iodinated contrast media within the preceding 7 to 10 days.
- Acute kidney injury from any cause present at admission or prior to contrast exposure.
- Active infection, sepsis, or systemic inflammatory response syndrome at the time of enrollment.
- Known history of gout, current use of urate-lowering therapy, or hematologic malignancy affecting uric acid metabolism.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of Participants With Contrast-Associated Acute Kidney Injury (CA-AKI)
Time frame: 72 hours post-procedure
Defined as an absolute increase in serum creatinine of at least 0.5 mg/dL (44.2 micromol/L) or a relative increase of at least 25% from baseline, evaluated within 72 hours following iodinated contrast media exposure.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
Related trials for Contrast-Induced Nephropathy
Recruiting
Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.
Contrast-induced Acute Kidney Injury (CI-AKI) Following Coronary Angiogram (CI-AKI), Contrast-induced Nephropathy Following Coronary Angiogram (CIN)
Not yet recruitingObservational study
An Observational Study of Percutaneous Glomerular Filtration Rate (TGFR) in the Early Warning of Contrast-induced Acute Kidney Injury During the Peri-examination Period of Emergency Enhanced CT
Contrast-associated Acute Kidney Injury
Not yet recruitingObservational study
Beyond the Mehran Risk Score: Predictive Value of Total Ischemic Time for Contrast-Induced Nephropathy in ST Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention.
ST Elevation (STEMI) Myocardial Infarction, Contrast Induced Nephropathy (CIN)
Not yet recruitingObservational study
Contrast Volume as a Predictor of Kidney Injury Following Contrast-Enhanced CT
Contrast-Associated Acute Kidney Injury, Acute Kidney Injury
Recruiting
Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure
Heart Failure Acute, Renal Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Contrast-Induced Nephropathy and Acute Kidney Injury, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Contrast-Associated Acute Kidney Injury (CA-AKI) (time frame: 72 hours post-procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.